AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9036412
Drug: Antileukemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antileukemic therapy
Trial: 4043711
Drug: 9-deoxy-16, 16-dimethyl-9-methylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-deoxy-16, 16-dimethyl-9-methylene prostaglandin E2 (vaginal suppository)
Trial: 24170677
Drug: Chronic anthocyanin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic anthocyanin consumption (500 mg/day)
Trial: 22771848
Drug: Simvastatin 80
RxNorm normalized name: simvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 80 mg daily for 8 weeks
Trial: 17387192
Drug: Oral sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sildenafil (0.3 mg x kg(‐1), every 3 hours for 24‐48 hours)
Trial: 16261199
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human interferon alpha‐2b for nasal spray
Trial: 29117180
Drug: Residual insecticide
RxNorm normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Residual insecticide treatment (RIT)
Trial: 25625810
Drug: Sequential intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential intervention (F/V+, Sed- first, then PA+)
Trial: 16844891
Drug: Medication-randomized clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication-randomized clinical trial scenario
Trial: 10831902
Drug: Immunotoxin MDX‐RA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotoxin MDX‐RA (low dose: 50 units)
Trial: 10831902
Drug: Immunotoxin MDX‐RA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotoxin MDX‐RA (high dose: 100 units)
Trial: 7894066
Drug: Interruption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interruption of hypertension therapy
Trial: 3128589
Drug: Cromolyn sodium
RxNorm normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cromolyn sodium by MDI (1 mg per actuation)
Trial: 22002175
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 or 200 mg/day)
Trial: 19224159
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy plus intravenous supplementation with omega‐3 fish oil emulsion 0.2 g/kg every day (FO group)
Trial: 19224159
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy plus intravenous supplementation with omega‐3 fish oil emulsion (FO group)
Trial: 12149668
Drug: Lercanidipine tablets
DrugBank: Lercanidipine (DB00528)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lercanidipine tablets 10 mg once-daily (n = 234)
Trial: 12149668
Drug: Losartan tablets
RxNorm normalized name: losartan Oral Tablet
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan tablets 50 mg once-daily (n = 231)
Trial: 9862408
Drug: Nicotine nasal
RxNorm normalized name: nicotine Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine nasal spray and nicotine gum
Trial: 320856
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (1,600 I.U. of d-alpha-tocopherol succinate daily) for 6 months
Trial: 16707911
Drug: Placebo therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo therapy for 6 months
Trial: 7030221
Drug: Aero-chamber with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aero-chamber with fenoterol (beta 2 stimulant)
Trial: 22093205
Drug: Adjusted dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted dose eptifibatide (1 μg/kg/min; eCrCl <50 ml/min)
Trial: 22093205
Drug: Excess dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Excess dose eptifibatide (2 μg/kg/min; eCrCl <50 ml/min)
Trial: 22093205
Drug: Early provisional
RxNorm normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early provisional treatment
Trial: 22093205
Drug: Delayed provisional
RxNorm normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed provisional treatment
Trial: 17588225
Drug: Hydrocortisone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (30 mg p.o.) with reboxetine (4 mg p.o.)
Trial: 10103294
Drug: Maintenance dose
RxNorm normalized name: Firmagon 80mg Powder for Injection Maintenance Dose Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance dose of stimulant medication
Trial: 7788958
Drug: Clarithromycin 250
RxNorm normalized name: clarithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 250 mg or 500 mg b.i.d.
Trial: 7788958
Drug: Cefaclor 250
RxNorm normalized name: cefaclor 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor 250 mg or 500 mg t.i.d.
Trial: 1979797
Drug: Antihistamines (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistamines (specific type not mentioned)
Trial: 417365
Drug: Baclofen (20‐120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (20‐120 mg daily)
Trial: 31669329
Drug: Ranibizumab treatment
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab treatment (7 monthly injections)
Trial: 31389581
Drug: B-ultrasound-guided puncture
RxNorm normalized name: MAGNI-GUIDE (B-D)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B-ultrasound-guided puncture treatment
Trial: 26068865
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin with a prandial GLP-1 receptor agonist (GLIPULIN)
Trial: 26068865
Drug: Basal-bolus insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal-bolus insulin (BBI)
Trial: 24368463
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy plus amitriptyline
Trial: 19427159
Drug: Morphine+Magnesium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine+Magnesium
Trial: 12414003
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL of 2% plain lignocaine
Trial: 12414003
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL of 0.9% sodium chloride solution (placebo)
Trial: 2236458
Drug: Clomipramine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (mean dosage 165 +/- 19 mg/day, reduced from 270 +/- 20 mg/day)
Trial: 2236458
Drug: Clomipramine (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (initial dosage 270 +/- 20 mg/day)
Trial: 27430425
Drug: sarolaner (Simparica™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sarolaner (Simparica™ Chewables) administered monthly for 3 months (2 to 4 mg/kg)
Trial: 27430425
Drug: fluralaner (Bravecto®)
RxNorm normalized name: fluralaner Topical Solution [Bravecto]
DrugBank: Fluralaner (DB11414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fluralaner (Bravecto®) administered as a single dose (25 to 56 mg/kg)
Trial: 7548266
Drug: Gallopamil 150
RxNorm normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallopamil 150 mg daily
Trial: 7548266
Drug: Gallopamil 50
RxNorm normalized name: gallopamil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallopamil 50 mg tid for 28 days
Trial: 7036825
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g daily intake of oral erythromycin base
Trial: 17617940
Drug: 2.3 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.3 g/d plant sterol supplementation
Trial: 17617940
Drug: 1.5 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g/d plant sterol supplementation
Trial: 12162476
Drug: gatifloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gatifloxacin (400 mg po 1 h)
Trial: 12162476
Drug: oxycodone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxycodone (5 mg po Q4H)
Trial: 12162476
Drug: gatifloxacin/oxycodone regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gatifloxacin/oxycodone regimen
Trial: 10658860
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy (n = 14)
Trial: 10658860
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (n = 16)
Trial: 1481703
Drug: Implicit preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implicit preparation instruction
Trial: 1481703
Drug: Explicit preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Explicit preparation instruction
Trial: 1481703
Drug: Random presentation
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Random presentation mode of preparation intervals
Trial: 1481703
Drug: Blocked presentation
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blocked presentation mode of preparation intervals
Trial: 1481703
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of implicit/explicit instructions and random/blocked presentation modes
Trial: 3969867
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate 10 mg every 2 hours for 72 hours
Trial: 18363889
Drug: Dexamethasone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (4 mg for 4 days)
Trial: 16797384
Drug: Nutrition intervention
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrition intervention targeting specific barriers (e.g., poor nutritional knowledge, help needed with shopping or cooking, difficulty swallowing)
Trial: 24645966
Drug: Single-dose (PEG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose (PEG 4 L the day before the study)
Trial: 24645966
Drug: Split-dose (2 L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-dose (2 L the day before and 2 L on the day of the procedure)
Trial: 24645966
Drug: Low-volume (2 L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-volume (2 L PEG solution the day of the procedure)
Trial: 16247428
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous (c.i.v.) administration of rhG-CSF
Trial: 16247428
Drug: Subcutaneous (s.c.)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (s.c.) administration of rhG-CSF
Trial: 3281489
Drug: Amodiaquine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amodiaquine (25 mg/kg over 3 days)
Trial: 3281489
Drug: Sulfadoxine-pyrimethamine (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine-pyrimethamine (single dose: 500 mg sulfadoxine and 25 mg pyrimethamine)
Trial: 16717297
Drug: Nonpulsatile CPB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonpulsatile CPB flow rates (2.4 L/min/m2 to either 1.8 or 3.0 L/min/m2)
Trial: 15058375
Drug: Enamel matrix
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enamel matrix derivative (EMD) combined with surgical treatment
Trial: 9455714
Drug: Ranitidine 2
RxNorm normalized name: ranitidine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 2 mg/kg with Metoclopramide 0.2 mg/kg
Trial: 9455714
Drug: Ranitidine 2
RxNorm normalized name: ranitidine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 2 mg/kg with Domperidone 0.3 mg/kg
Trial: 9455714
Drug: Famotidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 0.5 mg/kg with Metoclopramide 0.2 mg/kg
Trial: 9455714
Drug: Famotidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 0.5 mg/kg with Domperidone 0.3 mg/kg
Trial: 2731781
Drug: Ticlopidine 250
RxNorm normalized name: ticlopidine 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine 250 mg/day
Trial: 1103722
Drug: Gentamicin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin (1 mg/kg, 1-hour intravenous infusion)
Trial: 1103722
Drug: Sisomicin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sisomicin (1 mg/kg, 1-hour intravenous infusion)
Trial: 1103722
Drug: Tobramycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin (1 mg/kg, 1-hour intravenous infusion)
Trial: 1103722
Drug: All antibiotics
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All antibiotics tested
Trial: 27916398
Drug: Ruxolitinib 10
RxNorm normalized name: ruxolitinib 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib 10 mg twice daily
Trial: 27916398
Drug: Best available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Best available therapy (hydroxyurea, interferon, pegylated interferon, pipobroman, anagrelide, approved immunomodulators, or no cytoreductive treatment)
Trial: 26006222
Drug: Dex/Bup/Fen group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dex/Bup/Fen group (1 mL epidural dexmedetomidine 0.5 µg/kg)
Trial: 26006222
Drug: Bup/Fen group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bup/Fen group (intrathecal hyperbaric bupivacaine 5 mg and epidural mixture of 10 mL plain bupivacaine 0.25 % and fentanyl 50 μg)
Trial: 22674972
Drug: Nintendo Wii
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Nintendo Wii Fit® balance exercise programme (12 supervised 30-min sessions, twice a week for 6-7 weeks)
Trial: 18707821
Drug: 3 months
RxNorm normalized name: TABLET, DOSE PACK, 3 MONTHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 months of neoadjuvant hormonal therapy (flutamide and goserelin) before 66 Gy radiotherapy
Trial: 18707821
Drug: 8 months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 months of neoadjuvant hormonal therapy (flutamide and goserelin) before 66 Gy radiotherapy
Trial: 15625041
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (medical counseling on diet and health without drug treatment)
Trial: 11595000
Drug: PNU-142633 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PNU-142633 (50 mg)
Trial: 8061848
Drug: Spirapril 24
RxNorm normalized name: spirapril 24 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirapril 24 mg once daily
Trial: 31869474
Drug: Concurrent Exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent Exercise (CEX)
Trial: 29210627
Drug: Nevirapine extended
RxNorm normalized name: Nevirapine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nevirapine extended release (NVP-XR) 400 mg once daily
Trial: 29210627
Drug: Nevirapine immediate
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nevirapine immediate release (NVP-IR) 200 mg twice daily
Trial: 26380444
Drug: Qianjin Kouchuang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qianjin Kouchuang Jiawei Granule (QKJG), 20 g each time, twice per day.
Trial: 26380444
Drug: Kouyanqing Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kouyanqing Granule (KG), 20 g each time, twice per day.
Trial: 26380444
Drug: QKJG vs
RxNorm normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QKJG vs KG at day 3 after treatment.
Trial: 26380444
Drug: QKJG vs
RxNorm normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QKJG vs KG at day 7 after treatment.
Trial: 26380444
Drug: QKJG vs
RxNorm normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QKJG vs KG at month 12 after treatment.
Trial: 21525866
Drug: Prebiotic oligosaccharide
RxNorm normalized name: chitosan oligosaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotic oligosaccharide mixture (15 or 30 g scGOS/lcFOS/pAOS daily)
Trial: 18652320
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Estradiol Valerate 2 mg, qd for 20 days, followed by Medroxyprogesterone Acetate 4 mg, b.i.d for 10 days
Trial: 12753987
Drug: 3-ml lidocaine-adrenaline
RxNorm normalized name: LIDOCAINE HCL 1% INJ 3ML SYRINGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-ml lidocaine-adrenaline injection before tonsillectomy
Trial: 3551180
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (KABI fragment 2165) 1 X 2'500 anti-factor Xa IU
Trial: 3551180
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin 2 X 5'000 IU
Trial: 3551180
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (KABI fragment 2165) 1 X 7'500 anti-factor Xa IU
Trial: 20193834
Drug: OAC (warfarin-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC (warfarin-containing regimens)
Trial: 17894654
Drug: Mitemcinal 10
RxNorm normalized name: Mitemcinal
DrugBank: Mitemcinal (DB06587)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitemcinal 10 mg bid
Trial: 17894654
Drug: Mitemcinal 20
RxNorm normalized name: Mitemcinal
DrugBank: Mitemcinal (DB06587)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitemcinal 20 mg bid
Trial: 17894654
Drug: Mitemcinal 30
RxNorm normalized name: Mitemcinal
DrugBank: Mitemcinal (DB06587)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitemcinal 30 mg bid
Trial: 17894654
Drug: Mitemcinal 20
RxNorm normalized name: Mitemcinal
DrugBank: Mitemcinal (DB06587)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitemcinal 20 mg tid
Trial: 15196109
Drug: Ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5 mg kg(‐1) bolus followed by 2 microg kg(‐1) min(‐1) infusion)
Trial: 12452304
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (group 1, n=11)
Trial: 12452304
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (group 1) without cardiogenic shock
Trial: 12452304
Drug: Primary angioplasty
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary angioplasty (group 2) and conservative treatment (group 1) in cardiogenic shock
Trial: 7711987
Drug: Zetir (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zetir (10 mg cetirizine dihydrochloride)
Trial: 7711987
Drug: Zyrtek (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zyrtek (10 mg cetirizine dihydrochloride)
Trial: 2570799
Drug: chlorpheniramine maleate,
RxNorm normalized name: Chlorpheniramine Maleate, 4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chlorpheniramine maleate, 8 mg
Trial: 720103
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 0.05 ml of Finalgon Strong Ointment
Trial: 30694974
Drug: Combined histamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined histamine H1 and H2 receptor antagonists (Blockade)
Trial: 28637064
Drug: Glycopyrrolate (0.004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate (0.004 mg/kg IM)
Trial: 28637064
Drug: Placebo (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2.0 mL normal saline solution IM)
Trial: 10075160
Drug: PENTA vaccine
RxNorm normalized name: Pentam
DrugBank: Pentamidine (DB00738)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PENTA vaccine at 12 months
Trial: 10075160
Drug: PENTA vaccine
RxNorm normalized name: Pentam
DrugBank: Pentamidine (DB00738)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PENTA vaccine at 15 months
Trial: 10075160
Drug: PENTA vaccine
RxNorm normalized name: Pentam
DrugBank: Pentamidine (DB00738)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PENTA vaccine at 18 months
Trial: 7669467
Drug: Enoximone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone 0.5 mg kg‐1 i.v., followed by 5 micrograms kg‐1 min‐1
Trial: 31544379
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (200 mg, 3 times a day) and Vitamin E (100 mg, once a day) for oral administration for 12 weeks
Trial: 28408148
Drug: Brass wire
RxNorm normalized name: Brassica napus oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brass wire ligature treatment with mandibular third molar germectomy (group A)